Literature DB >> 17595235

Incidence of Guillain-Barré syndrome in Alberta, Canada: an administrative data study.

L J Hauck1, C White, T E Feasby, D W Zochodne, L W Svenson, M D Hill.   

Abstract

BACKGROUND: To examine the epidemiology of Guillain-Barré syndrome (GBS) in Alberta between 1994 and 2004 with data derived from hospital administration procedures.
METHODS: Data from 3,959,857 individuals (1,956,841 females and 2,003,016 males) aged 1-110 years and residing in Alberta, Canada, were included in the analysis. A Poisson regression analysis was performed to determine the predictors of GBS events.
RESULTS: After age and sex standardisation to the 2001 Canadian census population, incidence rates ranged from 0.97 to 2.32 per 100,000 over the course of the 11-year period, with a mean incidence of 1.6 per 100,000. Significant effects of gender, age group and year were found. Males were found to be 1.5 times more likely to acquire GBS than females. Relative to those in their first decade, the risk of acquiring GBS increased with advancing age, whereby the incidence in males peaked in the 7th decade of life and in females in the 8th decade of life. The incidence fluctuated over the 11-year period, with a minimum in 1998 and a maximum in 2004.
CONCLUSIONS: The incidence of GBS in Alberta between 1994 and 2004 fluctuated within a narrow range, was similar to that previously reported worldwide, demonstrated a male preponderance and increased in elderly patients.

Entities:  

Mesh:

Year:  2007        PMID: 17595235     DOI: 10.1136/jnnp.2007.118810

Source DB:  PubMed          Journal:  J Neurol Neurosurg Psychiatry        ISSN: 0022-3050            Impact factor:   10.154


  10 in total

Review 1.  Immune-mediated neuropathies.

Authors:  Bernd C Kieseier; Emily K Mathey; Claudia Sommer; Hans-Peter Hartung
Journal:  Nat Rev Dis Primers       Date:  2018-10-11       Impact factor: 52.329

2.  Incidence of Guillain-Barré syndrome (GBS) in China: A national population-based study.

Authors:  Pei Zheng; De-Cai Tian; Yuwen Xiu; Yongjun Wang; Fu-Dong Shi
Journal:  Lancet Reg Health West Pac       Date:  2021-11-02

3.  Development and validation of an administrative case definition for inflammatory bowel diseases.

Authors:  Ali Rezaie; Hude Quan; Richard N Fedorak; Remo Panaccione; Robert J Hilsden
Journal:  Can J Gastroenterol       Date:  2012-10       Impact factor: 3.522

Review 4.  Autonomic involvement in Guillain-Barré syndrome: an update.

Authors:  Zoya Zaeem; Zaeem A Siddiqi; Douglas W Zochodne
Journal:  Clin Auton Res       Date:  2018-07-17       Impact factor: 4.435

5.  Early predictors of Guillain-Barré syndrome in the life course of women.

Authors:  Nathalie Auger; Caroline Quach; Jessica Healy-Profitós; Trish Dinh; Michaël Chassé
Journal:  Int J Epidemiol       Date:  2018-02-01       Impact factor: 7.196

6.  Estimating background rates of Guillain-Barré Syndrome in Ontario in order to respond to safety concerns during pandemic H1N1/09 immunization campaign.

Authors:  Shelley L Deeks; Gillian H Lim; Mary Anne Simpson; Laura Rosella; Christopher O Mackie; Camille Achonu; Natasha S Crowcroft
Journal:  BMC Public Health       Date:  2011-05-17       Impact factor: 3.295

7.  Analysis of adverse events following immunization in Zhejiang, China, 2019: a retrospective cross-sectional study based on the passive surveillance system.

Authors:  Xuejiao Pan; Huakun Lv; Fuxing Chen; Ying Wang; Hui Liang; Linzhi Shen; Yaping Chen; Yu Hu
Journal:  Hum Vaccin Immunother       Date:  2021-06-25       Impact factor: 4.526

8.  Real-Time Surveillance of Infectious Diseases: Taiwan's Experience.

Authors:  Shu-Wan Jian; Chiu-Mei Chen; Cheng-Yi Lee; Ding-Ping Liu
Journal:  Health Secur       Date:  2017 Mar/Apr

9.  Prevalence and outcomes of Guillain-Barré syndrome among pediatrics in Saudi Arabia: a 10-year retrospective study.

Authors:  Safiyyah Asiri; Waleed A Altwaijri; Duaa Ba-Armah; Ahmed Al Rumayyan; Muhammad T Alrifai; Mahmoud Salam; Adel F Almutairi
Journal:  Neuropsychiatr Dis Treat       Date:  2019-03-01       Impact factor: 2.570

10.  Use of sugammadex in patients with neuromuscular disorders: a systematic review of case reports.

Authors:  Usha Gurunathan; Shakeel Meeran Kunju; Lisa May Lin Stanton
Journal:  BMC Anesthesiol       Date:  2019-11-19       Impact factor: 2.217

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.